These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 10136547)
1. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital. Coppola P Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547 [TBL] [Abstract][Full Text] [Related]
2. Experience with a two-tiered therapeutic interchange policy. Rich DS Am J Hosp Pharm; 1989 Sep; 46(9):1792-8. PubMed ID: 2572167 [TBL] [Abstract][Full Text] [Related]
6. Strategy for developing a safe and cost-effective H2-receptor antagonist program. Quercia RA; Chow MS; Jay GT; Quintiliani R Hosp Formul; 1991 Nov; 26 Suppl D():20-4. PubMed ID: 10136561 [TBL] [Abstract][Full Text] [Related]
7. Decision analysis applied to selection of histamine H2-receptor antagonists for the formulary. Calvo MV; Fruns I; DomÃnguez-Gil A Am J Hosp Pharm; 1990 Sep; 47(9):2002-6. PubMed ID: 1977316 [TBL] [Abstract][Full Text] [Related]
8. Rational selection of H2-receptor antagonists for the hospital formulary. Roundtable discussion. Keeffe EB; Harper JM; LeMay A; Sherrin TP; Siepler JK Hosp Formul; 1991 Nov; 26 Suppl D():13-9. PubMed ID: 10136560 [No Abstract] [Full Text] [Related]
9. A practice-based approach for converting from proton pump inhibitors to less costly therapy. Lucas LM; Gerrity MS; Anderson T Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299 [TBL] [Abstract][Full Text] [Related]
11. Criteria-based DUE aids in selection of preferred agent. Drea EJ Hosp Formul; 1991 Nov; 26 Suppl D():25-7. PubMed ID: 10136562 [TBL] [Abstract][Full Text] [Related]
12. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals. Segal R; Oh T; Ben-Joseph R; Russell WL Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic-interchange program for oral histamine H2-receptor antagonists. Chase SL; Peterson AM; Wordell CJ Am J Health Syst Pharm; 1998 Jul; 55(13):1382-6. PubMed ID: 9659966 [TBL] [Abstract][Full Text] [Related]
14. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine. Oh T; Franko TG Am J Hosp Pharm; 1990 Jul; 47(7):1547-51. PubMed ID: 2114789 [TBL] [Abstract][Full Text] [Related]
15. Effect of a criteria-based cost-containment program on the selection of oral H2-receptor antagonists. Falbe WJ; Bess DT; Capers CC; Haymond JD; Stahl AA Am J Hosp Pharm; 1992 Mar; 49(3):632-3. PubMed ID: 1598944 [No Abstract] [Full Text] [Related]
16. Pharmacy intern intervention to reduce costs associated with histamine H2-antagonist therapy. Algozzine GJ; Sprenger RL; Caselnova DA; Proper P Am J Hosp Pharm; 1989 Jun; 46(6):1183-4. PubMed ID: 2568750 [No Abstract] [Full Text] [Related]
17. Drug-use review program for concurrent histamine H2-receptor antagonist-sucralfate therapy. Kane MP; Briceland LL; Garris RE; Favreau BN Am J Hosp Pharm; 1990 Sep; 47(9):2007-10. PubMed ID: 1977317 [TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic aspects and formulary considerations related to histamine2-receptor antagonists. Souney PF; Stoukides CA DICP; 1989 Oct; 23(10 Suppl):S29-35. PubMed ID: 2573207 [TBL] [Abstract][Full Text] [Related]
19. An analysis of potential and real cost savings by the addition of ranitidine to total parenteral nutrition solutions. Pearson VE; King LM Hosp Pharm; 1992 Jul; 27(7):610, 613-4. PubMed ID: 10119189 [TBL] [Abstract][Full Text] [Related]
20. Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy. Kitrenos JG; Brown DR; Letting DJ; Rotella DL Hosp Formul; 1993 Jan; 28(1):86-8, 91, 95-6. PubMed ID: 10123271 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]